Practical considerations in the use of regorafenib in metastatic colorectal cancer

Therapeutic Advances in Medical Oncology
Fotios LoupakisTanios S Bekaii-Saab

Abstract

Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician-patient communication points to facilitate shared decision-making.

References

Apr 27, 2013·Molecular Cancer Therapeutics·Lotfi Abou-ElkacemWiltrud Lederle
Dec 18, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mieke De WitChiara Cremolini
May 15, 2015·The New England Journal of Medicine·Robert J MayerUNKNOWN RECOURSE Study Group
Jun 3, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B McLellanE Van Cutsem
Jul 29, 2015·Nature Reviews. Clinical Oncology·Chiara CremoliniFotios Loupakis
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Jul 12, 2016·Clinical Medicine Insights. Oncology·Fabien CalcagnoVirginie Nerich
Sep 3, 2016·Cancers·Eric Van CutsemThomas Seufferlein
Sep 18, 2016·Targeted Oncology·Katerina KopeckovaJana Prausova
Dec 21, 2016·Liver Cancer·Dominique EliasGuido Torzilli
May 5, 2017·European Journal of Endocrinology·Fabiana PaniStefano Mariotti
Nov 28, 2017·Cancer Treatment Reviews·Maria Røed SkårderudDorte Lisbet Nielsen
Feb 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D ArnoldJ Taieb
Dec 7, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ShitaraT Yoshino
Apr 24, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lara E DavisRobert G Maki
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ShitaraT Yoshino
Jun 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DucreuxUNKNOWN CORRELATE Investigators

❮ Previous
Next ❯

Citations

Sep 17, 2021·Frontiers in Oncology·Alexander SeryakovMaxim Sorokin

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01103323
NCT01584830
NCT01538680
NCT02310477
NCT02042144
NCT01959269
NCT01843400
NCT02699073
NCT01929616
NCT02368886

Software Mentioned

CONCUR
CONSIGN
CORRECT
SHARE
ReDOS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
F Boudinar, B Larbaoui
Clinical Advances in Hematology & Oncology : H&O
Axel GrotheyTanios S Bekaii-Saab
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
J SastreC Pericay
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Elena Mata VelascoRuth Vera
© 2021 Meta ULC. All rights reserved